Omzet 2024 * | 83,55 mln. 77,52 mln. | Omzet 2025 * | 77,08 mln. 71,52 mln. | Marktkapitalisatie | 18,65 mln. 17,31 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -12 mln. -11,13 mln. | Nettowinst (verlies) 2025 * | 2 mln. 1,86 mln. | EV/omzet 2024 * | 0,22 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,24 x |
K/w-verhouding 2024 * |
-1,5
x | K/w-verhouding 2025 * |
6,7
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,5% |
Recentste transcriptie over Aytu Bioscience Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joshua Disbrow
CEO | Chief Executive Officer | 49 | 16-04-15 |
Jarrett Disbrow
FOU | Founder | 49 | 16-04-15 |
Mark Oki
DFI | Director of Finance/CFO | 55 | 17-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Vivian Liu
BRD | Director/Board Member | 62 | 01-07-22 |
Jarrett Disbrow
FOU | Founder | 49 | 16-04-15 |
Joshua Disbrow
CEO | Chief Executive Officer | 49 | 16-04-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+29,98% | 682 mld. | |
+31,83% | 586 mld. | |
-3,52% | 364 mld. | |
+18,59% | 327 mld. | |
+4,07% | 285 mld. | |
+16,29% | 240 mld. | |
+9,50% | 209 mld. | |
-8,63% | 203 mld. | |
+7,09% | 165 mld. |